

Patronage



# 1. Alpe Adria Hematology Meeting 2024

March 15-16, 2024

Medical University of Graz

Graz, Austria

Organisation



Scientific partner



# PROGRAMME | Friday, March 15, 2024

12.45 Get Together

13.15 Welcoming Address  
Andreas REINISCH  
Rector Univ.-Prof. Dr. Andrea KURZ

## 13.30-15.05 SESSION I: MYELOID NEOPLASMS

Chair: Sill H. (Graz) 🇸🇮 | Tiribelli M. (Udine) 🇮🇹

NGS in the diagnostics of acute myeloid leukemias  
Duraković N. (Zagreb) 🇭🇷

Novel approaches for residual disease detection in AML  
Woelfer A. (Graz) 🇸🇮

Correlations between molecular features and clinical outcomes  
in acute and chronic myeloproliferative neoplasms  
Tiribelli M. (Udine) 🇮🇹

RAS-signaling in myeloid neoplasms:  
From bedside to bench and back again  
Zebisch A. (Graz) 🇸🇮

Azacitidine plus Venetoclax for the treatment of relapsed and  
refractory acute myeloid leukemia patients in Slovenia  
Škerget M. (Ljubljana) 🇸🇮

Genome engineering to model myeloid leukemogenesis  
Reinisch A. (Graz) 🇸🇮

Round Table Discussion  
Common interests & potential collaborations

15.05 Coffee Break



## 15.30-16.50 SESSION II: LYMPHOID NEOPLASMS

Chair: Aurer I. (Zagreb) 🇭🇷 | Zver S. (Ljubljana) 🇸🇮

Myelodysplasia-related molecular abnormalities and  
clonal hematopoiesis in patients with relapsed-refractory  
lymphoid malignancies receiving CAR-T cells  
Toffoletti E. (Udine) 🇮🇹

Secondary tumors after ASCT for multiple myeloma  
Batinić J. (Zagreb) 🇭🇷



NR4A family functions as tumor suppressors  
in diffuse large B cell lymphoma

Deutsch A. (Graz) 🇸🇰

Hemopoietic SC harvesting in the era of Daratumumab  
in patients with multiple myeloma

Poiani M. (Trieste) 🇮🇹

Several blood-based parameters at time of diagnosis are  
associated with the occurrence of an aggressive clinical  
course of follicular lymphoma

Feichtinger J. (Graz) 🇸🇰

**Round Table Discussion**

Common interests & potential collaborations

16.50

Coffee Break



17.15-18.15

**KEYNOTE LECTURE**

Chair: Jost P. (Graz) 🇸🇰

Metabolic adaptations driving drug resistance in acute myeloid  
leukemia: from basic studies to clinical perspectives

Jean-Emmanuel Sarry (Toulouse) 🇫🇷

19.45

**GET TOGETHER & DINNER | LANDHAUSKELLER GRAZ**



## PROGRAMME | Saturday, March 16, 2024

8.30-9.55

**SESSION III: BENIGN HEMATOLOGY &  
GENERAL TOPICS IN HEMATOLOGY**

Chair: Zaja F. (Trieste) 🇮🇹 | Reinisch A. (Graz) 🇸🇰

Emicizumab in hemophilia A patients with an urge of surgery –  
Slovenian data

Rener K. (Ljubljana) 🇸🇯

Applying research knowledge into clinical practice: From develop-  
ment of guidelines to diagnostic-therapeutic care pathways


Olivieri J. (Udine) 🇮🇹

N-glycosylation of immunoglobulin G in immune thrombocytopenia

Ranković E. (Zagreb) 🇭🇷

ITP: development of a new biologic diagnostic and  
prognostic profile: A GIMEMA Study

Lucchini E. (Trieste) 🇮🇹

Role of bacterial colonization in the outcome of patients with AML  
Mohamed S. (Trieste) 

### Round Table Discussion

Common interests & potential collaborations

09.55

Coffee Break



10.15-12.15


## SESSION IV: CELLULAR THERAPY (CAR-T, alloSCT)

Chair: Greinix H. (Graz)  | Pulanić D. (Zagreb) 


The role and place for allo HSCT in CLL and MM in the era of novel therapies: Slovenian data

Novak P. (Ljubljana) 


Tissue-based cellular biomarkers of acute GvHD

Gaksch L. (Graz) 

cGVHD team at UHC Zagreb 2013-2024: implementation of NIH criteria and scientific projects

Pulanić D. (Zagreb) 


Udine transplant program activity overview with a focus on post-SCT complications management and cellular therapies projects

Battista M. (Udine) 


Fecal Microbiota Transplantation (FMT) for the treatment of acute GvHD

Neumeister P. (Graz) 

CAR-T cell therapy for large B-cell lymphoma

Dreta B. (Zagreb) 

Challenges in CAR-T cell manufacturing

Schlenke P. (Graz) 

Path from pharma CAR-T to academical CAR-T in Slovenia

Sever M. (Ljubljana) 

### Round Table Discussion

Common interests & potential collaborations

12.15

## SUMMARY & FAREWELL



# SPONSORS

*We are grateful for the support  
of the following companies:*

## MAIN SPONSORS

The logo for Abbvie, featuring the word "abbvie" in a lowercase, blue, sans-serif font.

**AUSTRIA & SLOVENIA**

The logo for Bristol Myers Squibb, featuring a stylized purple and pink graphic of vertical bars of varying heights to the left of the text "Bristol Myers Squibb™" in a grey, sans-serif font.

## SPONSORS

AOP Health

Astellas

BeiGene Austria GmbH

Daiichi Sankyo

Exscientia

Gilead Sciences

Incyte Biosciences

Austria GmbH

Janssen-Cilag Pharma

Jazz Pharma

MSD

Pfizer Corporation

Austria GmbH

Roche Austria

Sanofi-Aventis GmbH

Servier Austria

Sobi

Stemline Therapeutics

Switzerland GmbH

TEVA ratiopharm



**Alpe Adria Hematology Meeting 2024**



# Alpe Adria Hematology Meeting 2024

## SCIENTIFIC COMMITTEE

Ass.-Prof. Dr. Andreas Reinisch, PhD  
Univ.-Prof. Dr. Heinz Sill  
*Division of Haematology &  
Department of Blood Group Serology and  
Transfusion Medicine  
Medical University of Graz, Austria*

## CPD ACCREDITATION

This event has been accredited for the CPD diploma of the Austrian Medical Chamber with **10 CLINICAL DFP CREDITS** in the medical specialty Internal Medicine (Hematology & Internal Oncology).



## REGISTRATION

Registration free of charge – only for medical professionals!

Please register online at

<https://www.onconovum.academy/anmeldung/alpeadria-hematology-meeting-2024>

## LOCATION

Medical University of Graz  
Med Campus Graz – lecture hall 5  
Neue Stiftingtalstraße 6, A-8036 Graz, Austria

### Public Transport

Tram stop: Line 7 – LKH Med Uni/Klinikum Nord  
Bus stop: Line 58 – St. Leonhard/Klinikum Mitte



REGISTER HERE

---

ONCONOVUM.ACADEMY – OeGHO Akademie für Aus- und Fortbildung GmbH  
Judengasse 11 / Top 6, A-1010 Vienna

**T** +43 (0)1 934 62 67 | **E** [academy@onconovum.at](mailto:academy@onconovum.at) | **W** [www.onconovum.academy](http://www.onconovum.academy)